{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T18:38:57Z","timestamp":1768070337784,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.jaad.2013.11.019","type":"journal-article","created":{"date-parts":[[2014,1,13]],"date-time":"2014-01-13T21:15:32Z","timestamp":1389647732000},"page":"709-715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Treatment of indolent primary cutaneous B-cell lymphomas with subcutaneous interferon-alfa"],"prefix":"10.1016","volume":"70","author":[{"given":"Staffan","family":"Vandersee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothea","family":"Terhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Humme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2013.11.019_bib1","first-page":"429","article-title":"Anti-tumor effects of interferon and its possible use as an anti-neoplastic agent in man","volume":"35","author":"Strander","year":"1977","journal-title":"Tex Rep Biol Med"},{"key":"10.1016\/j.jaad.2013.11.019_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2121-13-7","article-title":"PKC-\u03b4 mediates interferon-\u03b1-induced apoptosis through c-Jun NH2-terminal kinase activation","volume":"13","author":"Yanase","year":"2012","journal-title":"BMC Cell Biol"},{"key":"10.1016\/j.jaad.2013.11.019_bib3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis","volume":"8","author":"Chawla-Sarkar","year":"2003","journal-title":"Apoptosis"},{"key":"10.1016\/j.jaad.2013.11.019_bib4","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/sj.onc.1205179","article-title":"Mechanisms of interferon-alpha induced apoptosis in malignant cells","volume":"21","author":"Thyrell","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.jaad.2013.11.019_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/jcp.20137","article-title":"Alpha-interferon and its effects on signal transduction pathways","volume":"202","author":"Caraglia","year":"2005","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jaad.2013.11.019_bib6","first-page":"190","article-title":"Proliferation inhibitory effect of human alpha interferon on primary explants of Burkitt lymphoma: inverse relationship to patient survival","volume":"35","author":"Ernberg","year":"1981","journal-title":"Biomedicine"},{"key":"10.1016\/j.jaad.2013.11.019_bib7","first-page":"112","article-title":"Treatment of leukemias and lymphomas by interferons, II: phase II of the trial treatment of chronic lymphoid leukemia by human interferon alpha","volume":"36","author":"Misset","year":"1982","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jaad.2013.11.019_bib8","first-page":"77","article-title":"Low-grade non-Hodgkin's lymphoma in the adult: new therapeutic approaches","volume":"29","author":"Gisselbrecht","year":"1987","journal-title":"Nouv Rev Fr Hematol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2013.11.019_bib9","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO;2-M","article-title":"The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas","volume":"57","author":"Bunn","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2013.11.019_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000248098","article-title":"Treatment of cutaneous T cell lymphoma with intermediate doses of interferon alpha 2a","volume":"179","author":"Nicolas","year":"1989","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaad.2013.11.019_bib11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2133.1999.02704.x","article-title":"Long-term follow-up in 51 patients with mycosis fungoides and S\u00e9zary syndrome treated by interferon-alfa","volume":"140","author":"Jumbou","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.11.019_bib12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.4103\/0378-6323.86502","article-title":"Primary cutaneous follicle center lymphoma responsive to interferon alfa-2a","volume":"77","author":"Kavala","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2013.11.019_bib13","series-title":"Basic mechanism of physiologic and aberrant lymphoproliferation in the skin","first-page":"545","article-title":"Use of recombinant interferon alpha-2a in the treatment of cutaneous lymphomas of T- and B-cell lineage","author":"Cerroni","year":"1994"},{"key":"10.1016\/j.jaad.2013.11.019_bib14","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.11.019_bib15","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.11.019_bib16","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.11.019_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2013.11.019_bib18","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/j.1365-2133.2012.10896.x","article-title":"Evaluation of different methods in the follow-up of patients\u00a0with indolent types of primary cutaneous lymphomas","volume":"166","author":"Terhorst","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.11.019_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00000372-200404000-00006","article-title":"Primary cutaneous immunocytoma\/marginal zone B-cell lymphoma: a case with unusual course","volume":"26","author":"Demirkesen","year":"2004","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2013.11.019_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1468-3083.1999.tb00817.x","article-title":"Primary\u00a0cutaneous B-cell lymphoma: treatment with low dose intralesional recombinant interferon-alpha 2A","volume":"12","author":"Rubegni","year":"1999","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.11.019_bib21","first-page":"315","article-title":"Complete remission following recombinant interferon alpha-2a in a patient with diffuse large B cell cutaneous lymphoma","volume":"31","author":"Tourani","year":"1989","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1016\/j.jaad.2013.11.019_bib22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0959-8049(94)90101-5","article-title":"Complete remission of a primary cutaneous B cell lymphoma treated with intralesional recombinant interferon alpha-2a","volume":"30A","author":"Zenone","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2013.11.019_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s004320050144","article-title":"Complete response of a primary cutaneous T-cell-rich B cell lymphoma treated with interferon alpha2a","volume":"124","author":"Wollina","year":"1998","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jaad.2013.11.019_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000051734","article-title":"Large B-cell lymphoma of the leg\u2013complete remission with perilesional interferon alpha","volume":"203","author":"Wollina","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2013.11.019_bib25","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/10428190500399698","article-title":"Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma","volume":"47","author":"Cozzio","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2013.11.019_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/09546639609089540","article-title":"Intralesional natural interferon alpha in the treatment of Crosti's lymphoma (primary cutaneous B follicular center-cell lymphoma): report of four cases","volume":"7","author":"Parodi","year":"1996","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaad.2013.11.019_bib27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0190-9622(97)80405-7","article-title":"Borrelia burgdorferi\u2013associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a","volume":"36","author":"K\u00fctting","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.11.019_bib28","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bjd.12484","article-title":"Long-term outcome of intravenous therapy with\u00a0rituximab in patients with primary cutaneous B-cell lymphomas","volume":"169","author":"Brandenburg","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.11.019_bib29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/annonc\/mdn636","article-title":"Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients","volume":"20","author":"Valencak","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2013.11.019_bib30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2340\/00015555-1113","article-title":"Systemic rituximab in multifocal primary cutaneous follicle center lymphoma","volume":"91","author":"Qu\u00e9reux","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2013.11.019_bib31","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/archderm.141.9.1139","article-title":"Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases","volume":"141","author":"Hoefnagel","year":"2005","journal-title":"Arch Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213012747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213012747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:30:51Z","timestamp":1759271451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962213012747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0190962213012747"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2013.11.019","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of indolent primary cutaneous B-cell lymphomas with subcutaneous interferon-alfa","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}